Tata Sons–funded MedTherapy is sharpening its India strategy with plans to build a large-scale manufacturing base for CAR-T and other gene therapies out of its New Delhi facility, aiming to slash both production time and cost for advanced oncology treatments. The Boston-headquartered biotech, founded in 2018 by former Novartis and Harvard-affiliated experts, positions itself as a fully integrated cell and gene therapy company spanning clinical development, viral vector manufacturing and contract development and manufacturing (CDMO) services for global partners.
At the core of its pitch is a proprietary platform that compresses CAR-T manufacturing timelines from the conventional four to six weeks to just a few days by re-engineering key process steps and leveraging in-house vector capability. MedTherapy says its technology enables rapid, scalable production of CAR-T cells and viral vectors at GMP grade, to make therapies significantly more affordable for patients in markets like India, where commercial CAR-T products remain largely inaccessible.
The company has set up a commercial-scale GMP manufacturing facility in New Delhi, spread over multiple levels and designed to handle large-volume production of virus vectors and CAR-T products for both its own pipeline and external clients. This India hub is backed by a technology development centre in Boston and is intended to serve as a global manufacturing node, supporting clinical and commercial supply for partners in the US, Europe and emerging markets while tapping India’s cost and talent advantages.
MedTherapy’s oncology pipeline includes CAR-T therapies for blood cancers and solid tumours such as brain, breast and lung cancers, alongside broader gene therapy programmes. By combining end-to-end CDMO services with its own product development, the company aims to address long-standing bottlenecks in cell and gene therapy manufacturing, particularly shortages and high prices of viral vectors, and support a “Make in India” model for next-generation cancer care.
